- Pharma Sahi Daam app or portal — in-app grievance submission, with the invoice attached
- NPPA helpline: 1800-111-255
- Email: monitoring-nppa@gov.in
What makes a complaint actionable rather than dismissed:
- A legible invoice or cash memo showing the date, facility name, batch, quantity and price charged
- The exact formulation and pack as billed
- The official price you are comparing against and where you found it (Pharma Sahi Daam screenshot, the displayed Form V list, or the pack label)
- The parcel or product photograph including the printed MRP, where relevant
Complaints also cover shortage or non-availability, not just price — which is the route to use when Paragraph 28(b) is being skirted.
⚖️ What Happens After You Complain
Overcharging is not treated as a billing error. DPCO 2013 sets out a recovery mechanism with interest:
- Paragraph 14(2) — a manufacturer selling a scheduled formulation above the ceiling price “shall be liable to deposit the overcharged amount along with interest thereon from the date of such overcharging.”
- Paragraph 20(2) — the same liability attaches to a manufacturer that raises the MRP of a non-scheduled formulation by more than 10% in twelve months.
- Paragraph 30 — empowers authorised Gazetted Officers to enter and search premises, seize drugs, and seize documents including cash memos, credit memo books, books of account and purchase/sale records.
So a complaint that names a specific bill, a specific product and a specific day feeds directly into an inspection power that reaches the shop’s own sales records. That is why the invoice matters more than the anecdote.
🏥 Hospital Pharmacies and Inpatient Billing — the Segment Everyone Misses
Hospitals and medical institutions are named compliance parties in the 13 November directive, and Paragraph 24(4)’s “every retailer and dealer” language does not carve them out. In practice, three problems recur in hospital billing:
- The price list is not displayed anywhere accessible to patients, so there is no reference point at the counter.
- The bill is not itemised to formulation and pack level, making it impossible to match a line item to a government price.
- Loose or unit-dose dispensing is billed at a per-unit rate that exceeds the pro-rata pack price — a Paragraph 27 issue.
If you are facing an inpatient bill, request the itemised statement with brand, strength, dosage form and units dispensed before discharge settlement. Without that breakdown you have nothing to compare against the regulator’s database, and the complaint route effectively closes.
⚠️ Five Pitfalls That Weaken an Otherwise Valid Claim
- Comparing a revised price to old stock. Stock manufactured before the notification may still carry the old printed MRP. Under Paragraph 26 the lower figure governs, but the retailer may legitimately hold the stock — the claim is about the price charged, not the label.
- Confusing a ceiling price with a fixed retail price. For scheduled formulations the ceiling is exclusive of local taxes as applicable; GST is added on top. A bill that exceeds the ceiling by the tax amount is not automatically an overcharge.
- Treating the 137-drug list as the whole market. The Paragraph 19 order covers 137 non-scheduled anti-cancer formulations. Everything else still runs on ceiling prices, the Paragraph 20 annual cap, or unrestricted MRP. Check which regime applies before alleging a breach.
- Assuming publication equals enforcement. The Action Taken Reports due on 16 November 2026 are the first compliance signal. Publication of a price list does not mean every retailer has updated.
- Filing without the invoice. A complaint citing a price but no bill cannot be matched to a transaction, and Paragraph 30’s seizure powers become unusable.
✅ Buyer’s Checklist
- Confirm the formulation, strength and pack size before discussing price
- Search Pharma Sahi Daam for the official price; note scheduled vs non-scheduled
- Compare the bill to both the official price and the pack MRP — the lower governs (Para 26)
- Ask to see the displayed Form V price list (Para 24(4))
- Check that loose tablets are not billed above the pro-rata pack price (Para 27)
- For hospital admissions, demand a formulation-level itemised bill before settlement
- Keep the invoice, batch details and a screenshot of the official price
- File via Pharma Sahi Daam, 1800-111-255, or monitoring-nppa@gov.in
- For shortage or refusal to sell, cite Paragraph 28 in the complaint
Price regulation in India is enforced through paperwork — displayed lists, Form V submissions, itemised invoices and Action Taken Reports. Patients who know which document to ask for are the ones who can actually use the ceiling. For buyers sourcing medicines through trade channels rather than retail, verifying that a distributor operates within these obligations is equally important — refer to IMSDA’s verified member directory for a list of IMSDA member distributors.
Sources
- Ministry of Chemicals and Fertilizers / Department of Pharmaceuticals, release dated 13 November 2026 — NPPA directive to State Drug Controllers, Action Taken Reports due 16 November 2026, display obligation, complaint channels, DPCO 2013 overcharging proceedings (as reported by New Kerala and Safir News, 13 November 2026)
- NPPA Gazette Order dated 17 October 2026 — Paragraph 19 DPCO 2013 trade margin cap of 30% on 137 non-scheduled anti-cancer drugs, effective 9 November 2026; Expert Committee constituted by DGHS
- Drugs (Prices Control) Order, 2013 (S.O. 1221(E) dated 15 May 2013, as amended) — Paragraphs 14(2), 19, 20, 24, 25, 26, 27, 28, 30, read from the NPPA published text at nppa.gov.in
- NPPA Office Memorandum dated 13 April 2016 — Paragraph 24 Form V price-list obligations on manufacturers
- NPPA Pharma Sahi Daam portal (nppaipdms.gov.in) — medicine price search, brand comparison and grievance submission
For more information, contact IMSDA at contact@indiamedicine.org.
On 13 November 2026, the National Pharmaceutical Pricing Authority (NPPA) wrote to every State Drug Controller in India with a single instruction: monitor compliance with the revised prices of 137 non-scheduled anti-cancer drugs, and file Action Taken Reports by 16 November 2026. The directive came with an explicit warning — violations “may attract overcharging proceedings under the provisions of the Drugs (Prices Control) Order (DPCO), 2013.”
Most coverage of this story has focused on the price cut itself. That misses the more useful half. A price notification only creates a legal ceiling; it does not put money back in a patient’s pocket unless someone actually checks the bill. This guide is about the enforcement machinery — what the law requires a pharmacy to display, what a hospital is obliged to show you, how to verify a price in under a minute, and what happens after you file a complaint.
🧾 What Actually Changed on 9 November 2026
The sequence matters, because each step creates a different legal obligation:
- 17 October 2026 — NPPA issued a Gazette Order capping the trade margin on 137 non-scheduled anti-cancer medicines at 30% of MRP, acting on the recommendation of an Expert Committee constituted by the Directorate General of Health Services (DGHS). The instrument used was Paragraph 19 of DPCO 2013, the “extraordinary circumstances / public interest” power that lets the Government fix or revise a price irrespective of the annual wholesale price index.
- 9 November 2026 — revised Maximum Retail Prices took effect.
- 11 November 2026 — revised price lists reflecting company submissions up to this date were uploaded to the NPPA website and the Pharma Sahi Daam app and portal.
- 13 November 2026 — the Ministry of Chemicals and Fertilizers announced that State Drug Controllers must strictly monitor the supply chain — manufacturers, stockists, dealers, retailers, hospitals and medical institutions — and submit Action Taken Reports to NPPA by 16 November 2026.
Note the composition of that list. It does not stop at the retail chemist. Hospitals and medical institutions are named as compliance parties, which is significant for anyone buying cancer medicines as an inpatient or through a hospital pharmacy.
📋 Your Right to See the Price List — Paragraph 24(4) DPCO 2013
This is the provision almost nobody invokes, and it is the most practical one in the entire order. DPCO 2013, Paragraph 24 — titled “Carrying into effect the price fixed or revised by the Government, its display and proof thereof” — imposes a chain of display duties. The sub-paragraphs that matter to a buyer:
- Para 24(2) — the manufacturer must print the MRP on the label of the container and the minimum pack offered for retail sale, “in indelible print mark,” preceded by the words “Maximum Retail Price” and followed by “inclusive of all taxes.”
- Para 24(3) — the manufacturer must issue a price list and supplementary price list in Form V to dealers, State Drug Controllers and the Government, referencing the price fixation or revision.
- Para 24(4) — “Every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.”
Read that last clause carefully. The price list is not a document the shop may produce on request from a back office. It must be on “a conspicuous part of the premises” and “easily accessible to any person wishing to consult the same.” If the list is absent, in a drawer, or illegible, the retailer is in breach of the display duty independently of whether the price charged was correct.
Paragraph 25(3) extends the same display obligation to non-scheduled formulations — which is the category the 137 cancer drugs sat in before the Paragraph 19 order. So even for medicines outside direct price control, the price list display duty applies.
🔍 The Two-Clause Rule That Settles Most Disputes
If a chemist tells you the printed MRP does not govern what they charge, two short paragraphs answer it:
- Paragraph 26 — Control of sale prices: “No person shall sell any formulation to any consumer at a price exceeding the price specified in the current price list or price indicated on the label of the container or pack thereof, whichever is less.”
- Paragraph 27 — Sale of split quantities: “No dealer shall sell loose quantity of any formulation at a price which exceeds the pro-rata price of the formulation.”
Paragraph 26 is the workhorse. The ceiling is whichever of the two figures is lower — so if a revised price list has brought the legal price below the MRP still printed on old stock, the lower number wins. Paragraph 27 closes the loophole where a strip is broken and individual tablets are billed at a per-unit rate that quietly exceeds the pack’s pro-rata price.
There is one more clause worth knowing when a pharmacy claims it is out of stock: Paragraph 28(b) states that no dealer shall withhold from sale or refuse to sell any drug available with him to a customer intending to purchase such drug. Paragraph 28(a) applies the same rule to manufacturers and distributors refusing to supply dealers.
📱 Step-by-Step: Verifying a Price Before You Pay
NPPA’s Pharma Sahi Daam app and portal give you the regulator’s own price database. It is free, with no subscription tier. The workflow that actually resolves disputes:
- Note the exact product identity — brand name, active ingredient and strength, dosage form, and pack size. Prices are set per formulation and pack, so “letrozole 2.5 mg” alone is not enough; you need the pack.
- Search Pharma Sahi Daam at nppaipdms.gov.in/NPPA/PharmaSahiDaam/searchMedicine or in the mobile app. The result tells you whether the formulation is scheduled (ceiling price fixed by government) or non-scheduled (price monitored, MRP set by manufacturer).
- Compare against the bill and against the printed pack MRP. Under Paragraph 26, the lower of the two governs.
- Check for a same-composition alternative. The app supports comparison across brands with identical active ingredients — a legitimate way to reduce cost, but any switch must be cleared with your treating oncologist first.
- Ask to see the displayed price list. This is your Paragraph 24(4) right, and it is the fastest way to establish whether the retailer is compliant on the disclosure duty.
⚠️ Do not substitute a cheaper equivalent on your own. For anti-cancer drugs, small differences in formulation, bioavailability or excipients are not clinically interchangeable in every regimen. Price comparison is for the conversation with your doctor, not a decision to make at the counter.
📮 How to File an Overcharging Complaint — and Where It Goes
The 13 November 2026 release names the official channels explicitly:
- Pharma Sahi Daam app or portal — in-app grievance submission, with the invoice attached
- NPPA helpline: 1800-111-255
- Email: monitoring-nppa@gov.in
What makes a complaint actionable rather than dismissed:
- A legible invoice or cash memo showing the date, facility name, batch, quantity and price charged
- The exact formulation and pack as billed
- The official price you are comparing against and where you found it (Pharma Sahi Daam screenshot, the displayed Form V list, or the pack label)
- The parcel or product photograph including the printed MRP, where relevant
Complaints also cover shortage or non-availability, not just price — which is the route to use when Paragraph 28(b) is being skirted.
⚖️ What Happens After You Complain
Overcharging is not treated as a billing error. DPCO 2013 sets out a recovery mechanism with interest:
- Paragraph 14(2) — a manufacturer selling a scheduled formulation above the ceiling price “shall be liable to deposit the overcharged amount along with interest thereon from the date of such overcharging.”
- Paragraph 20(2) — the same liability attaches to a manufacturer that raises the MRP of a non-scheduled formulation by more than 10% in twelve months.
- Paragraph 30 — empowers authorised Gazetted Officers to enter and search premises, seize drugs, and seize documents including cash memos, credit memo books, books of account and purchase/sale records.
So a complaint that names a specific bill, a specific product and a specific day feeds directly into an inspection power that reaches the shop’s own sales records. That is why the invoice matters more than the anecdote.
🏥 Hospital Pharmacies and Inpatient Billing — the Segment Everyone Misses
Hospitals and medical institutions are named compliance parties in the 13 November directive, and Paragraph 24(4)’s “every retailer and dealer” language does not carve them out. In practice, three problems recur in hospital billing:
- The price list is not displayed anywhere accessible to patients, so there is no reference point at the counter.
- The bill is not itemised to formulation and pack level, making it impossible to match a line item to a government price.
- Loose or unit-dose dispensing is billed at a per-unit rate that exceeds the pro-rata pack price — a Paragraph 27 issue.
If you are facing an inpatient bill, request the itemised statement with brand, strength, dosage form and units dispensed before discharge settlement. Without that breakdown you have nothing to compare against the regulator’s database, and the complaint route effectively closes.
⚠️ Five Pitfalls That Weaken an Otherwise Valid Claim
- Comparing a revised price to old stock. Stock manufactured before the notification may still carry the old printed MRP. Under Paragraph 26 the lower figure governs, but the retailer may legitimately hold the stock — the claim is about the price charged, not the label.
- Confusing a ceiling price with a fixed retail price. For scheduled formulations the ceiling is exclusive of local taxes as applicable; GST is added on top. A bill that exceeds the ceiling by the tax amount is not automatically an overcharge.
- Treating the 137-drug list as the whole market. The Paragraph 19 order covers 137 non-scheduled anti-cancer formulations. Everything else still runs on ceiling prices, the Paragraph 20 annual cap, or unrestricted MRP. Check which regime applies before alleging a breach.
- Assuming publication equals enforcement. The Action Taken Reports due on 16 November 2026 are the first compliance signal. Publication of a price list does not mean every retailer has updated.
- Filing without the invoice. A complaint citing a price but no bill cannot be matched to a transaction, and Paragraph 30’s seizure powers become unusable.
✅ Buyer’s Checklist
- Confirm the formulation, strength and pack size before discussing price
- Search Pharma Sahi Daam for the official price; note scheduled vs non-scheduled
- Compare the bill to both the official price and the pack MRP — the lower governs (Para 26)
- Ask to see the displayed Form V price list (Para 24(4))
- Check that loose tablets are not billed above the pro-rata pack price (Para 27)
- For hospital admissions, demand a formulation-level itemised bill before settlement
- Keep the invoice, batch details and a screenshot of the official price
- File via Pharma Sahi Daam, 1800-111-255, or monitoring-nppa@gov.in
- For shortage or refusal to sell, cite Paragraph 28 in the complaint
Price regulation in India is enforced through paperwork — displayed lists, Form V submissions, itemised invoices and Action Taken Reports. Patients who know which document to ask for are the ones who can actually use the ceiling. For buyers sourcing medicines through trade channels rather than retail, verifying that a distributor operates within these obligations is equally important — refer to IMSDA’s verified member directory for a list of IMSDA member distributors.
Sources
- Ministry of Chemicals and Fertilizers / Department of Pharmaceuticals, release dated 13 November 2026 — NPPA directive to State Drug Controllers, Action Taken Reports due 16 November 2026, display obligation, complaint channels, DPCO 2013 overcharging proceedings (as reported by New Kerala and Safir News, 13 November 2026)
- NPPA Gazette Order dated 17 October 2026 — Paragraph 19 DPCO 2013 trade margin cap of 30% on 137 non-scheduled anti-cancer drugs, effective 9 November 2026; Expert Committee constituted by DGHS
- Drugs (Prices Control) Order, 2013 (S.O. 1221(E) dated 15 May 2013, as amended) — Paragraphs 14(2), 19, 20, 24, 25, 26, 27, 28, 30, read from the NPPA published text at nppa.gov.in
- NPPA Office Memorandum dated 13 April 2016 — Paragraph 24 Form V price-list obligations on manufacturers
- NPPA Pharma Sahi Daam portal (nppaipdms.gov.in) — medicine price search, brand comparison and grievance submission
For more information, contact IMSDA at contact@indiamedicine.org.
